|
Applied Biosystems Inc. (formerly Applera Corp) |
|
|
45 West Gude Drive
Rockville, MD 20850-1159 USA
phone:(240) 453-3000
fax:(203) 840-2000
|
|
| Symbol |
ABI |
| Exchange |
NASDAQ |
| Founded |
1998 |
| Employees |
530 |
|
|
| http://www.applera.com/
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| (Formerly Applera) Leverages proteomics, bioinformatics and genomics capabilities for drug therapies. |
|
| Management |
| Paul Arata, Vice President, Human Resources and Administration; Samuel Broder, Chief Medical Officer; Christopher Hall, Chief Business Officer of Berkeley HeartLab; Joel Jung, Chief Financial Officer; Scott Milsten, Vice President, General Counsel and Corporate Secretary; Kathy Ordo?ez, Chief Executive Officer; Stacey Sias, Chief Business Officer; G. Russell Warnick, Chief Scientific Officer, Berkeley HeartLab, Inc.; Thomas White, Chief Scientific Officer, Celera; Michael Zoccoli, General Manager - Products Business |
| |
|
|
|
|
|
|
| Recent Results |
| The Company has agreements with large pharmaceutical companies and internal programs for discovering therapeutics for inflammatory diseases, including asthma, osteoporosis and rheumatoid arthritis. |
| |
|
|
|
|
| Keywords |
| diagnostics, genome, proteomics, bioinformatics, inflammation, coagulation, oncology, Applera Corp |
|
|
|
| Description |
|
Celera Genomics, a business segment of Applera Corporation, is principally engaged in integrating advanced technologies to discover and develop therapeutics. The Company intends to leverage its capabilities in proteomics, bioinformatics and genomics to identify and validate drug targets, and to discover and develop new therapeutics either on its own or in collaboration with other companies. Celera Genomics expects to use these capabilities with its molecular and cell biology, medicinal and computational chemistry, pharmacology and other drug development technologies to optimize the potency, selectivity and physical properties of new drug candidates. |
|
| Products / Services |
Celera Genomics is building a product portfolio based on its expertise in medicinal chemistry, structure-based drug design, proteomics and genomics. Initial focus areas include inflammation, coagulation, and oncology. The company has partnered with Merck to develop Cathepsin K inhibitors for osteoporosis, Maxim Pharmaceuticals to develop Apoptosis Inducers for cancer, and with Aventis to develop Cathepsin S inhibitors for inflammatory and autoimmune diseases.
|
|
| Technology / Differentiation |
| Celera Genomics was founded to sequence and assemble the human genome to which it completed a first draft sequence in two years. The Company then sequence the mouse genome in nine months and build the Celera Discovery System online platform, providing scientists access to these genomes, as well as annotation, biological information and comparative genomic tools. |
|
|
| Competitors / Substitutes / Alternatives |
Human Genome Sciences Inc (HGSI) Incyte Corporation (INCY) Zymogenetics Inc (ZGEN)
|
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
